GlobalData on MSN3d
Bio-Thera signs US deal with Intas for golimumab biosimilar
Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.
moneycontrol.com6y
Intas Pharmaceuticals
Intas Pharma becomes most valuable privately held pharma company A PE deal values Intas at Rs 23,000 crore or USD 3.5 billion, making it the most valued pharma privately held company in India.
Contract Pharma3d
Accord, Bio-Thera Partner on Simponi Biosimilar BAT2506
Accord BioPharma Inc., the U.S. specialty division of Intas Pharmaceuticals Ltd., has reached an exclusive commercialization and license agreement with Bio-Thera Solutions for BAT2506, a biosimilar ...
Medindia9mon
Intas Pharmaceuticals Ltd., Ahmedabad
Learn about Intas Pharmaceuticals Ltd. in Ahmedabad, Gujarat.Find comprehensive contact details, including phone numbers and email addresses, and get directions to the location. If you own or are ...
PipelineReview.com3d
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...